Logo

Jim Golden, Myra Williams

Apr 08, 2002
Premium

Jim Golden, formerly director of bioinformatics at New Haven, Conn.-based CuraGen, has moved on to serve as business development manager at the company’s technology spin-off, 454 Corp.

454, under wraps since its launch on June 2000, “will come out of stealth mode soon,” said Golden.

Myra Williams, former CIO for Glaxo and former president and CEO of Molecular Applications Group, has joined the scientific advisory board of cheminformatics company Synthematix. The company, based in Research Triangle Park, NC, also appointed Tom Cori, former chairman and CEO of Sigma-Aldrich, to its SAB.

Filed under

Informatics
Breaking News
The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.